Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)

Trial Profile

Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Acronyms HOPE
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 May 2017 Planned End Date changed from 1 Sep 2017 to 31 Mar 2018.
    • 05 May 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top